Ocumension Therapeutics has confirmed completion of the first patient enrollment in its Phase III clinical trial for OT-802 (pilocarpine hydrochloride) in mainland China, marking a critical development milestone for the presbyopia treatment program.

OT-802 is an internally developed formulation that leverages the same dual-chamber liquid-liquid technology applied in the company’s OT-101 (0.01% atropine sulfate eye drop). This proprietary platform is designed to enhance product stability, and Ocumension holds exclusive patent rights to the technology. Pre-clinical data cited by the company indicate rapid onset of action and a favorable safety profile for the asset.

Regulatory progress has been steady: China’s Center for Drug Evaluation under the National Medical Products Administration accepted the Phase III trial application in June 2025. The present milestone underscores continued execution against the study timeline.

Ocumension notes that successful development and commercialization of OT-802 remain subject to clinical outcomes and regulatory review, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.